Valneva Shares Fall 3.87% to €2.63 Following a 11.83% Surge the Previous Day
The stock of the Nantes-based vaccine specialist fell sharply this Tuesday morning to €2.63. Valneva is among the top 5 biggest losers in the SBF 120, with the broader index down 0.58% during the session. This movement comes after a significant rebound of 11.83% the previous day.
A Decline Following a 11.83% Rebound the Day Before
The stock fell 3.87% to €2.63, after recording the best rebound in the SBF 120 on Monday. The biotech remains the second largest loser in the broader index this Tuesday, behind Teleperformance (-4.5%). Today's movement does not undermine the weekly performance: Valneva is still up 16.72% over seven days. However, over three months, the stock has declined by 35.2%, a period marked by Goldman Sachs' downgrade to 'sell' at the end of April and a reserved offer of 84 million euros completed on April 30. The SBF 120 is down 0.58% in the session, while the CAC 40 loses 0.61%.
Price Moves Above the MM20, Below Two Longer Moving Averages
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The price is above the 20-day moving average (€2.46), with a gap of nearly 7%. However, it remains below the MM50 at €3.28 and the MM200 at €3.87, indicating that the medium and long-term dynamics are still deteriorated. The RSI at 53 is neutral, showing no directional signal. The upper Bollinger Band at €2.76 is approaching, with the price located in the upper part of the band at 79%. On the agenda, the 2026 general assembly is scheduled for June 1, followed by a second session on June 25. Valneva will also participate in the Bernstein European Small & Mid-Cap Conference on May 21.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 65,8 millions d'euros
Quarterly revenue: 65,8 millions d'euros
Revenue growth: -32,6 %
EBITDA: -39,8 millions d'euros
Net income: -63,3 millions d'euros
Guidance from the release
Malgré l'impact négatif persistant du contexte géopolitique sur les voyages, Valneva a confirmé ses perspectives pour 2026
Risks mentioned
Impact négatif persistant du contexte géopolitique sur les voyages affectant les ventes de produits
Dépendance commerciale élevée envers les livraisons d'IXIARO au Département américain de la Défense avec calendrier incertain
Recentrage stratégique d'IXCHIQ sur les marchés endémiques affectant les perspectives commerciales du vaccin contre le chikungunya
Opportunities identified
Décisions réglementaires attendues pour le candidat vaccin LB6V contre la maladie de Lyme dans les 12 prochains mois
Amélioration attendue des marges brutes au second semestre après impact d'éléments non récurrents au S1 2026
Bénéfices futurs de l'initiative de restructuration visant à réduire la consommation de trésorerie et optimiser les opérations
Outlook / guidance
Expected revenue: 147,5 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
